Literature DB >> 31115671

Letter to the editors of the Journal of Cancer Research and Clinical Oncology.

H Matthes1, R-D Hofheinz2, G Bar-Sela3, D Galun4, D Martin5, R Huber6, J Langhorts7, P F Matthiessen8, F Schad9.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31115671     DOI： 10.1007/s00432-019-02926-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  3 in total

Review 1.  Mistletoe in oncological treatment: a systematic review : Part 1: survival and safety.

Authors:  M Freuding; C Keinki; O Micke; J Buentzel; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-23       Impact factor: 4.553

2.  Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.

Authors:  Wilfried Tröger; Danijel Galun; Marcus Reif; Agnes Schumann; Nikola Stanković; Miroslav Milićević
Journal:  Dtsch Arztebl Int       Date:  2014-07-21       Impact factor: 5.594

3.  Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.

Authors:  W Tröger; D Galun; M Reif; A Schumann; N Stanković; M Milićević
Journal:  Eur J Cancer       Date:  2013-07-24       Impact factor: 9.162
  3 in total
  2 in total

1.  Untargeted metabolomics approach to discriminate mistletoe commercial products.

Authors:  Cécile Vanhaverbeke; David Touboul; Nicolas Elie; Martine Prévost; Cécile Meunier; Sylvie Michelland; Valérie Cunin; Ling Ma; David Vermijlen; Cédric Delporte; Stéphanie Pochet; Audrey Le Gouellec; Michel Sève; Pierre Van Antwerpen; Florence Souard
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

2.  Statement to an Insufficient Systematic Review on Viscum album L. Therapy.

Authors:  Harald Matthes; Anja Thronicke; Ralf-Dieter Hofheinz; Erik Baars; David Martin; Roman Huber; Thomas Breitkreuz; Gil Bar-Sela; Daniel Galun; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-18       Impact factor: 2.629
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.